Richard Kefford

Professor

  • 29727 Citations
  • 76 h-Index
1980 …2022
If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Professor Richard Kefford AM MB BS PhD FRACP is Professor of Cancer Medicine and former Head of Department, Department of Clinical Medicine at Macquarie University, Sydney and Co-Director of Research at Melanoma Institute Australia. He is an internationally acclaimed melanoma researcher and a national leader in academic medicine and medical research with a life-long record of commitment and service to Australian medical research, peer review, professional training and mentoring and community education in oncology. He contributed to the mapping and characterisation of the major melanoma susceptibility genes and the development of international guidelines on genetic testing of those at high melanoma risk. He played a pivotal role in the development of life-extending drug treatments now used as standard-of-care for melanoma, including the first-time in human trial of dabrafenib, the pioneering use of dabrafenib and trametinib for patients with brain metastases, and the Phase 1 clinical trial of pembrolizumab.

Fingerprint Dive into the research topics where Richard Kefford is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles
Melanoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Mutation Medicine & Life Sciences
Survival Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Skin Medicine & Life Sciences
Mitogen-Activated Protein Kinase Kinases Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2014 2022

Centre for Research Excellence in Implementation Science in Oncology (CRE-ISO)

Braithwaite, J., Ward, R., Currow, D., Delaney, G., Kefford, R., Olver, I., Karnon, J., Crowe, P., Liauw, W., Westbrook, J., Meiser, B., Tieman, J., Verspoor, K., Ellis, L., Krishnasamy, M., Ayliff, N., Hawkins, N., Hibbert, P., Farnsworth, R. & Clay-Williams, R.

1/12/1730/11/22

Project: Other

Acquired resistance to PD1 inhibition in melanoma

Rizos, H., Carlino, M., Kefford, R., Zhang, X. D., Menzies, A. M., Long, G., McGuire, H., Yang, J., Scolyer, R. & De St Groth, B. F.

1/01/17 → …

Project: Research

Determinants of response to immune checkpoint inhibitors in melanoma

Rizos, H., Long, G., Menzies, A. M., Yang, J., Carlino, M., Kefford, R., Scolyer, R., MQRES, M., MQRES 3 (International), M. 3. & De St Groth, B. F.

1/01/17 → …

Project: Research

Molecular determinants of risk, progression and treatment response in melanoma

Kefford, R., Thompson, J., Hersey, P., Mann, G., Scolyer, R., Hayward, N. & Long, G.

1/01/16 → …

Project: Research

Research Outputs 1980 2020

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: analysis from phase 2 and 3 clinical trials

Hauschild, A., Ascierto, P. A., Schadendorf, D., Grob, J. J., Ribas, A., Kiecker, F., Dutriaux, C., Demidov, L. V., Lebbé, C., Rutkowski, P., Blank, C. U., Gutzmer, R., Millward, M., Kefford, R., Haas, T., D'Amelio, A., Gasal, E., Mookerjee, B. & Chapman, P. B., 1 Jan 2020, In : European Journal of Cancer. 125, p. 114-120 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Phase III Clinical Trials
Melanoma
Dacarbazine
Disease-Free Survival
dabrafenib

Analysis of the whole-exome sequencing of tumor and circulating tumor DNA in metastatic melanoma

Diefenbach, R. J., Lee, J. H., Strbenac, D., Yang, J. Y. H., Menzies, A. M., Carlino, M. S., Long, G. V., Spillane, A. J., Stretch, J. R., Saw, R. P. M., Thompson, J. F., Ch'ng, S., Scolyer, R. A., Kefford, R. F. & Rizos, H., 29 Nov 2019, In : Cancers. 11, 12, p. 1-14 14 p., 1905.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Exome
Melanoma
DNA
Neoplasms
Mutation

Associations of pigmentary and naevus phenotype with melanoma risk in two populations with comparable ancestry but contrasting levels of ambient sun exposure

Cust, A. E., Drummond, M., Bishop, D. T., Azizi, L., Schmid, H., Jenkins, M. A., Hopper, J. L., Armstrong, B. K., Aitken, J. F., Kefford, R. F., Giles, G. G., Demenais, F., Goldstein, A. M., Barrett, J. H., Kanetsky, P. A., Elder, D. E., Mann, G. J. & Newton-Bishop, J. A., Oct 2019, In : Journal of the European Academy of Dermatology and Venereology. 33, 10, p. 1874-1885 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Nevus
Solar System
Melanoma
Phenotype
Population

bcGST: an interactive bias-correction method to identify over-represented gene-sets in boutique arrays

Wang, K. Y. X., Menzies, A. M., Silva, I. P., Wilmott, J. S., Yan, Y., Wongchenko, M., Kefford, R. F., Scolyer, R. A., Long, G. V., Tarr, G., Mueller, S. & Yang, J. Y. H., 15 Apr 2019, In : Bioinformatics. 35, 8, p. 1350-1357 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Bias Correction
Genes
Gene
Test Set
Annotation

Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1 based immunotherapy

Lim, S. Y., Lee, J. H., Nur Gide, T., Menzies, A. M., Guminski, A., Carlino, M. S., Breen, E., Yang, J. Y. H., Ghazanfar, S., Kefford, R. F., Scolyer, R. A., Long, G. V. & Rizos, H., Mar 2019, In : Clinical Cancer Research. 25, 5, p. 1557-1563 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Immunotherapy
Melanoma
Cytokines
Confidence Intervals
Therapeutics